The Immunogenicity of Branded and Biosimilar Infliximab in Rheumatoid Arthritis According to Th9-Related Responses

Our objective was to evaluate the immunogenicity of branded and biosimilar infliximab by detecting changes in T-helper-9 (Th9) percentages induced by an in vitro stimulation test. Methods: Peripheral blood mononuclear cells collected from 55 consecutive rheumatoid arthritis (RA) outpatients (15 drug...

Descripción completa

Detalles Bibliográficos
Autores principales: Talotta, Rossella, Berzi, Angela, Doria, Andrea, Batticciotto, Alberto, Ditto, Maria Chiara, Atzeni, Fabiola, Sarzi-Puttini, Piercarlo, Trabattoni, Daria
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2017
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5666809/
https://www.ncbi.nlm.nih.gov/pubmed/29023386
http://dx.doi.org/10.3390/ijms18102127

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5666809/
https://www.ncbi.nlm.nih.gov/pubmed/29023386
http://dx.doi.org/10.3390/ijms18102127

Ejemplares similares